Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery

The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development

XtalPi, an AI-powered drug R&D company, has expanded its strategic collaboration with Pfizer to advance its AI-driven drug discovery and materials science simulations.

The partnership aims to develop a next-generation molecular modelling platform, enhancing the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development.

Under this expansion of their collaboration, the two teams will focus on developing more accurate predictive models to Pfizer's proprietary chemical space, with the aim of further empowering small molecule drug discovery and development across a broader range of research applications.

 In the collaboration, XtalPi will deploy its XFEP platform, from parameter customization to FEP calculations, for Pfizer to use in its drug discovery efforts.

With the goals of improved accuracy, high-throughput speed, and user-friendly interface, the platform will be designed to support Pfizer scientists across diverse drug design and development scenarios.

"Pfizer's leadership in pharmaceutical innovation and their deep scientific expertise have been invaluable in shaping the evolution of our AI-driven platform," said Dr. Jian Ma, CEO of XtalPi. "This collaboration demonstrates the transformative potential of XtalPi's computational platform combining physics-based insights with advanced AI technology, and propels us to develop even more powerful predictive tools. Together, we are building up a new platform for drug discovery, potentially unlocking possibilities that were once out of reach and accelerating the delivery of life-changing therapies for patients worldwide."

XtalPi CEO Jian Ma said: “Pfizer’s leadership in pharmaceutical innovation and their deep scientific expertise have been invaluable in shaping the evolution of our AI-driven platform.

“This collaboration demonstrates the transformative potential of XtalPi’s computational platform combining physics-based insights with advanced AI technology and propels us to develop even more powerful predictive tools.

“Together, we are building up a new platform for drug discovery, potentially unlocking possibilities that were once out of reach and accelerating the delivery of life-changing therapies for patients worldwide.”